- Home
- LPX vs STVN Comparison
LPX vs STVN Comparison
Compare LPX & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPX
- STVN
- Stock Information
- Founded
- LPX 1973
- STVN 1949
- Country
- LPX United States
- STVN Italy
- Employees
- LPX N/A
- STVN N/A
- Industry
- LPX Forest Products
- STVN Containers/Packaging
- Sector
- LPX Basic Materials
- STVN Consumer Discretionary
- Exchange
- LPX Nasdaq
- STVN Nasdaq
- Market Cap
- LPX 6.2B
- STVN 6.6B
- IPO Year
- LPX N/A
- STVN 2021
- Fundamental
- Price
- LPX $89.99
- STVN $22.14
- Analyst Decision
- LPX Buy
- STVN Buy
- Analyst Count
- LPX 8
- STVN 6
- Target Price
- LPX $108.13
- STVN $25.08
- AVG Volume (30 Days)
- LPX 851.0K
- STVN 326.1K
- Earning Date
- LPX 05-06-2025
- STVN 05-08-2025
- Dividend Yield
- LPX 1.24%
- STVN 0.27%
- EPS Growth
- LPX 56.47
- STVN N/A
- EPS
- LPX 5.71
- STVN 0.50
- Revenue
- LPX $2,941,000,000.00
- STVN $1,215,562,040.00
- Revenue This Year
- LPX $0.31
- STVN $8.42
- Revenue Next Year
- LPX $7.25
- STVN $10.44
- P/E Ratio
- LPX $15.77
- STVN $44.76
- Revenue Growth
- LPX 8.09
- STVN 3.81
- 52 Week Low
- LPX $78.82
- STVN $16.56
- 52 Week High
- LPX $122.87
- STVN $25.75
- Technical
- Relative Strength Index (RSI)
- LPX 47.46
- STVN 46.39
- Support Level
- LPX $89.98
- STVN $21.97
- Resistance Level
- LPX $94.87
- STVN $24.43
- Average True Range (ATR)
- LPX 2.19
- STVN 1.28
- MACD
- LPX -0.33
- STVN -0.21
- Stochastic Oscillator
- LPX 7.59
- STVN 7.67
About LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.